Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2013-05-19 Capital/Financing Update
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
GTG executes sixth PPO agreement 2 pages 614.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated May 20, 2013, regarding Genetic Technologies Limited executing an agreement with a nationwide Provider Network (MultiPlan). It discusses the business development of credentialing agreements to increase covered lives for their BREVAGen test. There is no financial data, no detailed financial report, no management discussion of financial results, no voting results, no legal proceedings, no executive changes, no merger or acquisition details, and no regulatory certifications. The document is a business update announcement about a contract execution and network expansion. It is not a report or transcript but a corporate announcement about a capital or business development activity. This fits best under Capital/Financing Update (CAP) as it relates to agreements that impact the company's commercial network and potential revenue streams. The document length is over 5,000 characters and contains substantive content about the agreement, not just a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2013-05-19 English
Settlement Agreement executed with LabCorp 1 page 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated May 6, 2013, reporting the execution of a settlement agreement between Genetic Technologies Limited and Laboratory Corporation of America Holdings. It discusses the background of a license agreement, arbitration, and the settlement reached, with confidentiality on commercial terms. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about a legal settlement, not a full audit report or legal proceedings update with detailed litigation information. It is not a report publication announcement since it contains substantive information about the settlement. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Legal Proceedings Report or M&A Activity. The document is under 5,000 characters and is a formal announcement to the market about a settlement agreement, consistent with RNS filings.
2013-05-05 English
GTG executes fifth PPO agreement 2 pages 117.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated May 3, 2013, regarding Genetic Technologies Limited executing an agreement with a nationwide Provider Network (Three Rivers Provider Network). The content focuses on the details of the agreement, its impact on reimbursement claims, and the company's strategy for credentialing with PPOs. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a business agreement and operational update rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a management or board change announcement, nor a legal or merger-related filing. Given the nature of the content as a business update announcement, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length (6717 characters) and content support this classification with high confidence.
2013-05-02 English
Settlement with Genetics & IVF Institute Inc. 1 pag
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated April 30, 2013, reporting the execution of a settlement agreement resolving litigation between Genetic Technologies Limited and Genetics & IVF Institute, Inc. It mentions the dismissal of the lawsuit and confidentiality of commercial terms. The document is a brief announcement about legal proceedings resolution, not a full legal proceedings report or financial report. It does not contain financial data, management discussion, or detailed legal analysis, but rather a summary update on a legal matter. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 3052 characters, which is short and consistent with an announcement rather than a full report. Hence, the classification is LTR with high confidence.
2013-04-29 English
ASX Appendix 4C and quarterly activities report 10 pages 51.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 March 2013'. It contains detailed operational updates, financial summaries, licensing and IP activities, corporate matters, and a consolidated statement of cash flows for the quarter. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year, along with the quarterly period specified, indicates this is a comprehensive interim financial report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2013
2013-04-29 English
GTG executes agreement with PreventionGenetics 1 pa
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated April 29, 2013, reporting the execution of a Settlement and License Agreement between Genetic Technologies Limited and PreventionGenetics, LLC. It references a legal dispute and its resolution but does not contain financial statements, detailed financial data, or comprehensive report content. The document is relatively short (3233 characters) and serves as a disclosure of a legal settlement rather than a full report or detailed financial filing. It is not an Annual Report, Interim Report, Earnings Release, or any detailed financial or management report. The content focuses on legal settlement information, which aligns with updates on significant lawsuits or regulatory actions involving the company. Therefore, the most appropriate classification is Legal Proceedings Report (LTR).
2013-04-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.